The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

The heavy selling pressure might have exhausted for Oxford Square Capital (OXSQ) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and which played a key role in maintaining Gilead's EBIT margin above 38% are Biktarvy, Livdelzi, and Yescarta. Meanwhile, the sales dynamics of its oncology franchise left me with mixed feelings, including due to the increasing pressure from more effective CAR T-cell therapies, bispecific antibodies, and ADCs.

CW is a solid pick in the aerospace defense equipment industry, given its growth prospects, better debt management and shareholder-friendly initiatives.

From a technical perspective, Bilibili (BILI) is looking like an interesting pick, as it just reached a key level of support. BILI recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

While the top- and bottom-line numbers for Sunrun (RUN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

While the top- and bottom-line numbers for Cenovus (CVE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

FTSE Russell has released the preliminary list of additions and deletions for its 2025 Russell US Indexes Reconstitution, marking the beginning of an annual process that updates the composition of its widely followed benchmarks. The reconstitution, based on April 30 market data, reflects shifts in company size, sector composition, and style classifications.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=150225&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.

MONTREAL, May 26, 2025 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today plans to invest approximately $290 million CAD in Saskatchewan, as part of its 2025 capital investment program. This investment will support track maintenance and strategic infrastructure initiatives in the province. This includes major projects to support customer initiatives and our agriculture industry partners to improve the movement of grain and fertilizers. These investments will help ensure the safe movement of goods and support long-term sustainable growth in Saskatchewan and across CN's network.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=150216&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Digimarc Corporation (NASDAQ:DMRC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/digimarc-corporation-lawsuit-submission-form-2?prid=150217&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150220&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your BigBear.ai Holdings, Inc. (NYSE:BBAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bigbear-ai-holdings-inc-lawsuit-submission-form?prid=150222&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Krispy Kreme, Inc. (NASDAQ:DNUT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/krispy-kreme-inc-lawsuit-submission-form?prid=150223&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Napco Security Technologies, Inc. (NASDAQ:NSSC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/napco-security-technologies-inc-lawsuit-submission-form-2?prid=150224&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Solaris Energy Infrastructure, Inc. (NYSE:SEI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/solaris-energy-infrastructure-inc-lawsuit-submission-form?prid=150218&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your SoundHound AI, Inc. (NASDAQ:SOUN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/soundhound-ai-inc-lawsuit-submission-form?prid=150226&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq.

SNPS' fiscal second-quarter performance is likely to have benefited from robust demand in the AI and high-performance computing end markets.

Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.